Good day and thank you for standing by. Welcome to the Innospec's Fourth Quarter, 2021, Earnings Release and Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please, be advised that today's conference is being recorded. [Operator Instructions] I would now like to turn the conference over to your speaker today, David Jones, General Counsel. Please, go ahead.

Thank you. Welcome to Innospec earnings call for the quarter, and year-end December 31st, 2021. The earnings release in this presentation are posted on the company site at innospecinc.com. During this call, we will make forward-looking statements which are predictions, projections, and other statements about future events. These statements are based on current expectations, and assumptions that are subject to risks, and uncertainties that could cause actual results to differ materially from the anticipated results implied by forward-looking statements. These risks and uncertainties are detailed Innospec's 10-K, 10-Qs, and other filings with the SEC. Visit the SEC site or Innospec's site for these and other documents. In our discussion today, we've also included some non-GAAP financial measures. A reconciliation from most directly comparable GAAP financial measures is contained in our earnings release. The non-GAAP financial measures should not be considered as a substitute for a superior to those prepared in accordance with GAAP. They are included as additional clarification items to aid investors in further understanding the company's performance in addition to the impact that these items expense have on financial results. With us today from Innospec are Patrick Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer. That, I'll turn it over to you, Patrick.

Thank you, David. And welcome, everyone, to Innospec's Fourth Quarter 2021 Conference Call. I'm pleased to present another very strong set of quarterly results for Innospec. Despite sustained supply chain labor and inflationary headwinds, we ended the year with record quarterly sales and full-year operating income up 74% on the prior year. Cash flow was extremely strong in the quarter, and our net cash position improved to a $140 million. In addition, today we announced that our board has approved a new $50 million share repurchase program. I'm extremely proud of the way our Innospec team has navigated this year's volatile market conditions to deliver these strong set of quarterly results and full-year results. Our business teams remained safe, resourceful, and customer-focused throughout this challenging year. We believe we are entering 2022 well-positioned for a continued innovation and growth in all our businesses. Performance Chemicals achieved record quarterly sales and surpass the $0.5 billion in full-year sales for the first time. The business delivered its fourth consecutive year of operating income growth and margin expansion with full-year operating income up an impressive 29% over 2020. With our $70 million organic growth investment plans in motion, and our new state-of-the-art Global Technology Center on track for completion by Q2 of this year, we are well-positioned to meet our customers' growing technology demands. Customers and consumers want sustainability, but they also want high performance. This dual requirement will continue to drive exciting, technology-lead future growth opportunities across all our Performance Chemical in markets. Fuel Specialties achieved record quarterly and full-year sales along with improved operating leverage. Gross margins ran below our target, 32% to 35% range. But this was primarily due to continued delay in jet fuel demand recovery, sales mix, and contract formula price increases, which naturally lag cost inflation. As…

Thanks, Patrick. Turning to Slide 7 in the presentation, the company's total revenues for the fourth quarter were $413.2 million. A 33% increase, and $310.8 million a year ago driven by recovering demand in all our businesses compared to our COVID impacted prior year. Overall, gross margin decreased by 2% points from last year to 27.3%. EBITDA for the quarter was $44.8 million, compared to $40.2 million last year. A net income for the quarter was $23.9 million, compared to $22.6 million a year ago. Our GAAP earnings per share were $0.96, including special items. The net effect of which decreased our fourth-quarter earnings, by $0.34 per share. A year ago, we reported GAAP earnings per share of $0.91, which included the negative impact from special items, of $0.36 per share. Excluding special items in both years, our adjusted EPS for the quarter was a $1.30 compared to $1.27 a year ago. For the full year, total revenues of $1.5 billion increased 24% from $1.2 billion in 2020. EBITDA for the year was $178.2 million compared to $108.9 million in 2020. And net income was $93.1 million compared to $28.7 million a year ago. Our full-year GAAP earnings per share were $3.75, including special items, which decreased our full-year earnings by $1.05 per share. In 2020, we reported GAAP earnings of $1.16 per share, which included the negative impact from special items of $2.06 per share. Excluding special items in both years, our adjusted EPS for the year was $4.80 compared to $3.22 a year ago. Turning to Slide 8, revenues in Performance Chemicals for the fourth quarter were $138.4 million, up 21% from last year's $114.6 million. Volumes grew 2% with a positive price mix of 21%, offsetting an adverse currency impact of 2%. Gross margins of 21.4% were…

Thanks, Ian. Entering 2022, we expect tight supply chain and elevated costs inflation to continue. It is imperative that our business teams maintain their sharp focus on technology, customer service, pricing, and gross margin management. We are cautiously optimistic that these conditions will moderate the coming quarters. And we are well-positioned for continued growth and margin expansion in all businesses. Our portfolio is dominated by technologies that are critical to the performance of personal care, cleaning, and other daily use applications, including more sustainable and cleaner transportation. Further price increases have been announced in all businesses in the first quarter. And in parallel, we continue to introduce innovative products which can help offset the impact of higher prices to our customers through enhanced performance. Our businesses did an excellent job managing cash and working capital during the quarter, increasing our net cash position to over $140 million. We will continue to create value for our shareholders through our disciplined execution of our capital allocation programs. These include funding our well-defined pipeline of organic growth projects, pursuing complementary acquisitions, and increasing capital returns to shareholders through dividend growth in our newly announced $50 million share buyback facility. Now I will turn the call over to the Operator, and Ian and I will take your questions.

Thank you. [Operator Instructions] Your first question today comes from the line of Jon Tanwanteng from CJS Securities. Please, go ahead. Your line is open.

Hi. Thank you. Good morning, everyone. [Indiscernible]

Hey, Jon. [Indiscernible]

[Indiscernible] I was wondering, can you talk about your high-level expectations for pricing versus volume as the component -- as components of your revenue growth? In each of the segments as we go forward, I assume there's more pricing coming, but I'm wondering on the volume side of that expectation, specifically, how -- what are you thinking there as we enter Q1, into 2022?

Jon, let me start for that one, then I'm sure Patrick will come up with some comments. So just going through the individual businesses, and as we've been talking throughout 2021, we're really pleased with where, performance chemicals is in a really sweet spot. We're expecting to high single-digit growth and we expect most of that growth to come through volume. Now there will be a raw material impact that will sort of in-flight. Those revenues are little bit likely have done in 2021. The underlying in the business we expected. High single-digit growth, mainly three volumes. Fuel Specialties is slightly different. Fuel Specialties has now to reached back to that pre-COVID diesel demand globally. We still got a little bit more to come in terms of volume from jet fuel, but that will come slowly throughout 2022. You may well see a little bit more volume in fuel specialties, but overall, that's a business that will settle back into that low single-digit growth rates. Again, we'll see some price inflation in the revenue line there, but underlying, you will expect to see probably 1% to 2% volume growth in that business. [Indiscernible] field is really the one where we're little bit uncertain at the moment. Customer activity is slowly returning. We're capturing our share of the market, and we'd expect the business to perform better than it has done in 2021. So again, we're optimistic that we'll continue to see good volume growth there as well.

I think Jon, it's been -- It's nice to see volume growth versus just pricing activity. And it's been consistent throughout all three businesses as you alluded to yourself. We're pretty confident, we're very happy with the quarter, we're very happy with the year-end results.

Okay, great. Thank you for that color and it's also nice to see that you're expecting gross margin improvement in Q1. I was wondering if you guys had talked about OpEx as we go forward as well as is there inflation that you need to address there as well, especially in terms of wage inflation and employee retention?

Yeah, Jon, we're -- like everybody else in the industry and the wider economy, we are seeing a lot of wage inflation. We've seen a lot of raw material inflation, freight, trucking, you name it. It's all coming through. We're very clear that our people are our key assets. We want to do everything we can to attract the best talent and retain the best talent. So, we're taking action across all of our businesses around wages, and working conditions, and flexibility. So yes, we'll see -- you'll see us do a lot more of that. How that impacts our operating expenses? We've baked all that into our numbers. It will add some pressure onto operating margins, but we think it's the right thing to do, and we'll set the correct action, whichever part of the world we're operating in.

Okay, great. Just a question on the buyback authorization, is that more of an opportunistic thing where you're waiting for some opportunity or is that something you plan to execute rather quickly on? Just given what the alternatives are in your capital allocation strategy.

It's a little bit of both Jon. It's being opportunistic in the marketplace. It's preventing dilution. It's a little bit of both, and I think that you'll see that because we have such a balanced capital allocation program, that this is easily manageable. And we would like to see this continue moving forward as the years move on. So, I think we're in a good spot. We've really identified a great growth program in Performance Chemical over the next five-years, where our capital allocation's going. We've increased the dividend between 10% to 12% every year. We want to continue doing that. But I think along with a nice share buyback and potentially increasing over time as well, puts us in a really good position.

Got it. And one final one for me if I could, just the 70 million in an ounce investment, can you break that up between product lines and end-markets and what you are actually putting the money into?

Yeah Jon. Let me say that at the first go. So, the $70 million are over -- just over two years with having investments first, and we're investing both in the US and Europe. We're investing in across a number of our facilities. The primary focus of that initially will be in the personal care markets, but we'll also be investing capacity into our home care markets, and that will also support our growing business in agriculture, and industrial, and mining as well. So, if the primary focus will be personal care, and that's the part of the business that we are seeing the most growth right now, but we're not just blind to the other part of our business as well. So, most of that will go into capacity expansions, and the infrastructure that's needed around our [Indiscernible] to manage that growth, be it chunking, piping, or wherever it might be. So, there's an awful lot going on, Jon. It's a multiyear program and we're well on with it right now. And that's what's going to support that high single-digit growth not just into 2022, but also into '23 and '24 and beyond.

Yes. I think just to add to that, Jon, it's all based around sustainability, natural, etc. And that's really been the themes all along. And that's the theme of our growth moving forward. And I think as Ian said, typically when we add expansion and other reactors, that volumes typically already spoken for. And so, it's a really nice program that's put in place with some nice contracts to back it. And it's all based around sustainability, long-term sustainability, and natural.

Got it. Thanks, guys. I'll jump back in queue.

Thank you.

Thanks, Jon.

Thank you. I will now hand the call back to Patrick Williams for closing remarks.

Thank you all for joining us today. And thanks to all our shareholders, customers, and Innospec employees for your interest and support. If you have any further questions about Innospec or matters discussed today, please give us a call. We look forward to being up with you again to discuss our first-quarter 2022 results in May. Have a great day.

Thank you. That does conclude today's conference. Thank you for participating. You may all disconnect.